Global Lead, Biologics Bioanalysis
Novartis Institutes for BioMedical Research, Inc.
East Hanover, New Jersey
Rob Dodge has worked in CMC manufacturing developing analytical release assays for Biologic therapeutics and Bioanalytical laboratories developing and carrying out regulated bioanalytical analysis of small molecule and protein drugs, as well as protein biomarkers and analysis of novel molecular entities such as nucleic acids, cell therapy, CRISPR, and gene therapy products. Rob is currently the Director Scientific Governance – Low Molecular Weight and Biological Products at Novartis with his team working across the development portfolio from late Discovery to Marketed products.
Disclosure information not submitted.
Wednesday, October 19, 2022
10:00 AM – 10:30 AM ET